TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.

Standard

TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. / Ramakers-van Woerden, N L; Pieters, R; Loonen, A H; Hubeek, I; van Drunen, E; Beverloo, H B; Slater, R M; Harbott, J; Seyfarth, J; van Wering, E R; Hählen, K; Schmiegelow, K; Janka-Schaub, Gritta; Veerman, A J.

in: BLOOD, Jahrgang 96, Nr. 3, 3, 2000, S. 1094-1099.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Ramakers-van Woerden, NL, Pieters, R, Loonen, AH, Hubeek, I, van Drunen, E, Beverloo, HB, Slater, RM, Harbott, J, Seyfarth, J, van Wering, ER, Hählen, K, Schmiegelow, K, Janka-Schaub, G & Veerman, AJ 2000, 'TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.', BLOOD, Jg. 96, Nr. 3, 3, S. 1094-1099. <http://www.ncbi.nlm.nih.gov/pubmed/10910927?dopt=Citation>

APA

Ramakers-van Woerden, N. L., Pieters, R., Loonen, A. H., Hubeek, I., van Drunen, E., Beverloo, H. B., Slater, R. M., Harbott, J., Seyfarth, J., van Wering, E. R., Hählen, K., Schmiegelow, K., Janka-Schaub, G., & Veerman, A. J. (2000). TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. BLOOD, 96(3), 1094-1099. [3]. http://www.ncbi.nlm.nih.gov/pubmed/10910927?dopt=Citation

Vancouver

Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. BLOOD. 2000;96(3):1094-1099. 3.

Bibtex

@article{236801ea32684e53b26ff428a4f8ccea,
title = "TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.",
abstract = "The t(12;21) translocation resulting in TEL/AML1 gene fusion is present in approximately 25% of patients with precursor B-lineage pediatric acute lymphoblastic leukemia (ALL). Studies suggest an association with a good prognosis; however, relapse can occur. We studied the relation between t(12;21), determined by fluorescence in situ hybridization or polymerase chain reaction, and in vitro drug resistance, measured by the MTT assay, in childhood B-lineage ALL at diagnosis. A total of 180 ALL samples were tested, 51 (28%) of which were positive for t(12;21). The median LC(50) values did not differ significantly between TEL/AML1-positive and -negative samples for prednisolone, dexamethasone, daunorubicin, thiopurines, epipodophyllotoxins, and 4-HOO-ifosfamide. However, the TEL/AML1-positive patients were relatively more sensitive to L-asparaginase (ASP; 5.9-fold; P =.029) and slightly but significantly more resistant to vincristine (1.5-fold; P =.011) and cytarabine (1.5-fold; P =.014). After matching for unevenly distributed patient characteristics-that is, excluding patients younger than 12 months, patients with CD10-negative immature B-lineage ALL, patients with Philadelphia chromosome, and patients who were hyperdiploid (more than 50 chromosomes) from the TEL/AML1 negative group-the only remaining difference was a relative sensitivity for ASP in the TEL/AML1-positive samples (10.8-fold; P =. 012). In conclusion, the presence of TEL/AML1 gene fusion in childhood precursor B-lineage ALL does not seem to be associated with a high in vitro drug sensitivity, except for ASP, indicating that these patients could benefit from treatment schedules with significant use of this drug.",
author = "{Ramakers-van Woerden}, {N L} and R Pieters and Loonen, {A H} and I Hubeek and {van Drunen}, E and Beverloo, {H B} and Slater, {R M} and J Harbott and J Seyfarth and {van Wering}, {E R} and K H{\"a}hlen and K Schmiegelow and Gritta Janka-Schaub and Veerman, {A J}",
year = "2000",
language = "Deutsch",
volume = "96",
pages = "1094--1099",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

RIS

TY - JOUR

T1 - TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.

AU - Ramakers-van Woerden, N L

AU - Pieters, R

AU - Loonen, A H

AU - Hubeek, I

AU - van Drunen, E

AU - Beverloo, H B

AU - Slater, R M

AU - Harbott, J

AU - Seyfarth, J

AU - van Wering, E R

AU - Hählen, K

AU - Schmiegelow, K

AU - Janka-Schaub, Gritta

AU - Veerman, A J

PY - 2000

Y1 - 2000

N2 - The t(12;21) translocation resulting in TEL/AML1 gene fusion is present in approximately 25% of patients with precursor B-lineage pediatric acute lymphoblastic leukemia (ALL). Studies suggest an association with a good prognosis; however, relapse can occur. We studied the relation between t(12;21), determined by fluorescence in situ hybridization or polymerase chain reaction, and in vitro drug resistance, measured by the MTT assay, in childhood B-lineage ALL at diagnosis. A total of 180 ALL samples were tested, 51 (28%) of which were positive for t(12;21). The median LC(50) values did not differ significantly between TEL/AML1-positive and -negative samples for prednisolone, dexamethasone, daunorubicin, thiopurines, epipodophyllotoxins, and 4-HOO-ifosfamide. However, the TEL/AML1-positive patients were relatively more sensitive to L-asparaginase (ASP; 5.9-fold; P =.029) and slightly but significantly more resistant to vincristine (1.5-fold; P =.011) and cytarabine (1.5-fold; P =.014). After matching for unevenly distributed patient characteristics-that is, excluding patients younger than 12 months, patients with CD10-negative immature B-lineage ALL, patients with Philadelphia chromosome, and patients who were hyperdiploid (more than 50 chromosomes) from the TEL/AML1 negative group-the only remaining difference was a relative sensitivity for ASP in the TEL/AML1-positive samples (10.8-fold; P =. 012). In conclusion, the presence of TEL/AML1 gene fusion in childhood precursor B-lineage ALL does not seem to be associated with a high in vitro drug sensitivity, except for ASP, indicating that these patients could benefit from treatment schedules with significant use of this drug.

AB - The t(12;21) translocation resulting in TEL/AML1 gene fusion is present in approximately 25% of patients with precursor B-lineage pediatric acute lymphoblastic leukemia (ALL). Studies suggest an association with a good prognosis; however, relapse can occur. We studied the relation between t(12;21), determined by fluorescence in situ hybridization or polymerase chain reaction, and in vitro drug resistance, measured by the MTT assay, in childhood B-lineage ALL at diagnosis. A total of 180 ALL samples were tested, 51 (28%) of which were positive for t(12;21). The median LC(50) values did not differ significantly between TEL/AML1-positive and -negative samples for prednisolone, dexamethasone, daunorubicin, thiopurines, epipodophyllotoxins, and 4-HOO-ifosfamide. However, the TEL/AML1-positive patients were relatively more sensitive to L-asparaginase (ASP; 5.9-fold; P =.029) and slightly but significantly more resistant to vincristine (1.5-fold; P =.011) and cytarabine (1.5-fold; P =.014). After matching for unevenly distributed patient characteristics-that is, excluding patients younger than 12 months, patients with CD10-negative immature B-lineage ALL, patients with Philadelphia chromosome, and patients who were hyperdiploid (more than 50 chromosomes) from the TEL/AML1 negative group-the only remaining difference was a relative sensitivity for ASP in the TEL/AML1-positive samples (10.8-fold; P =. 012). In conclusion, the presence of TEL/AML1 gene fusion in childhood precursor B-lineage ALL does not seem to be associated with a high in vitro drug sensitivity, except for ASP, indicating that these patients could benefit from treatment schedules with significant use of this drug.

M3 - SCORING: Zeitschriftenaufsatz

VL - 96

SP - 1094

EP - 1099

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 3

M1 - 3

ER -